Publication bias was explored using a funnel plot. The whole process of trials selection was demonstrated in Figure 1. The characteristics of included trials were listed in Table 2. Two of the trials did not report the gender, and male and female were included in the other 20 trials.
One trial [ 4 ] included patients with MI; five of the trials [ 5 , 27 , 28 , 34 , 39 ] included patients with unstable angina; two of the trials [ 6 , 38 ] included patients with ACS; three of the trials [ 21 , 22 , 31 ] included patients with stable angina. The other 11 trials [ 23 — 26 , 29 , 30 , 32 , 33 , 35 — 37 ] did not introduce the types of CHD or all types were included. The duration of treatment ranged from 4 weeks to 7 years. There were five comparisons in the review according to various control groups.
One trial [ 39 ] was designed as three groups with two comparisons and Xuezhikang and conventional therapy versus conventional therapy; Xuezhikang and conventional therapy versus atorvastatin and conventional therapy. According to the criteria introduced above, no trial was evaluated as having a low risk of bias.
Only one trial of the 22 trials reported the method to generate the allocation sequence random number table in the paper [ 6 ]. After we contacted with the authors, six trials announced a correct method for allocation sequence [ 4 — 6 , 31 , 33 , 35 ].
One trial was assessed as having adequate concealment [ 35 ]. Two trials applied double-blinding [ 4 , 35 ], and two trials used single-blinding but did give us objective to be blinded [ 25 , 37 ]. One trial blinded the outcome assessors [ 4 ]. One trial reported prior sample size estimation and mentioned intention-to-treat analysis [ 4 ].
There was only 1 trial [ 4 ] reported the all-cause mortality in the comparisons of Xuezhikang and conventional therapy versus placebo and conventional therapy [RR 0.
There were 5 studies [ 4 , 22 , 27 , 28 , 32 ] that presented the effect of Xuezhikang in reducing the mortality of CHD. Compared to simvastatin on the basis of conventional therapy, Xuezhikang showed no significant difference in mortality of CHD RR 0. Compared to no treatment on the basis of simvastatin and conventional therapy, Xuezhikang showed no effect in reducing mortality of CHD RR 0. Compared with inositol nicotinate on the basis of aspirin, Xuezhikang showed no significant difference in mortality of CHD RR 0.
There were 3 studies reporting CHD events in 3 different comparisons. Compared with placebo on the basis of conventional therapy, Xuezhikang showed a reduction of morbidity of MI RR 0.
Compared with simvastatin on the basis of conventional therapy, Xuezhikang showed no significant difference RR 0. In comparisons of Xuezhikang and simvastatin and conventional therapy versus simvastatin and conventional therapy, Xuezhikang showed no effect in reducing incidence of MI RR 0. There were 2 studies [ 4 , 28 ] reporting revascularization in 2 different comparisons.
Compared with placebo on the basis of conventional therapy, Xuezhikang showed a significant reduction of revascularization RR 0. Compared with simvastatin on the basis of conventional therapy, Xuezhikang showed no significant difference RR 1. There were 2 trials [ 27 , 28 ] reporting rehospitalization in 2 different comparisons.
Compared with simvastatin on the basis of conventional therapy, Xuezhikang showed no significant difference in the number of rehospitalization RR 1. Compared with no treatment on the basis of simvastatin and conventional therapy, Xuezhikang showed no effect in reducing rehospitalization RR 0. There were 21 studies that reported the level of total cholesterol Table 4 , but one trial only reported the serum lipid level of the treatment group [ 30 ].
Since there was significant heterogeneity in the comparison, we examined the data carefully and found that data of two trials deviated from the others.
Sensitive analysis was used and got a similar conclusion MD 0. There were 20 studies that reported the level of TG See Table 4 , but one trial only reported the serum lipid level of the treatment group [ 30 ]. Adjust abnormal blood lipid levels including lowering serum total cholesterol TC , serum triglyceride TG , low-density lipoprotein cholesterol LDL-C and increasing high-density lipoprotein cholesterol HDL-C ; inhibiting the formation of the atherosclerotic plaque and the deposition of fat in the liver and protecting the endotheliocyte in the vascular.
Take 2 capsules per time, 2 times after breakfast and supper per day. For patients suffering from slight or mode-rate hyperlipidemia, it is recommended to take 2 capsules after evening meal, or consult with your physician.
Occasional discomfort of intestine and stomach, such as stomachburn, intestinal gas and pain in the stomach, usually temporary and reversible increase of SGPT 0. Do not use Xuezhikang if you are pregnant, can become pregnant or are breast feeding. This product is slightly acidic in nature, and thus gastric and intestine reaction co-uld be reduced if it is taken after meals.
In case of slight gastric and intestine reactions, it is unnecessary to cease the administration. Privacy Policy.
Our Responsibility. Buyer Responsibility 1 Buyer refuse to sign for,the goods return and shipping costs are not refundable 2 Buyer provide with the wrong address, if the goods not returned, payment not refunded, if the goods be returned , the goods return and shipping costs are not refundable. If the goods be returned, the goods return and shipping costs are not refundable. Others Responsibility 1. Can not pass through the customs, goods return, we refund part of the money, the freight not refundable 2.
We regard each order goods you already understand ,that we do not accept to required returns or refunds because of goods you don't clear know, unless otherwise discuss 3. For general information, Learn About Clinical Studies. Hide glossary Glossary Study record managers: refer to the Data Element Definitions if submitting registration or results information.
Search for terms. Save this study. Warning You have reached the maximum number of saved studies Listing a study does not mean it has been evaluated by the U. Federal Government. Read our disclaimer for details. Results First Posted : May 19, Last Update Posted : May 19, Study Description. Both XueZhiKang and Statins are cholesterol-lowering medications that are often prescribed for individuals with high cholesterol and who are at risk for cardiovascular disease CVD.
Several studies, including one randomized, double-blind, placebo-controlled clinical trial, have suggested that the use of statins is more frequently associated with fatigue.
Detailed Description:. Drug Information available for: Simvastatin. FDA Resources. Arms and Interventions. Participants will receive mg of XueZhiKang twice a day for 4 weeks. Participants will receive 20mg of simvastatin daily for 4 weeks. Outcome Measures. Fasting blood samples were collected at weeks 0 randomization and 4 end of study for clinical chemistry.
0コメント